We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




AI Improves Completeness of Complex Cancer Pathology Reports

By LabMedica International staff writers
Posted on 10 Apr 2026

Oncology teams increasingly rely on pathology reports that integrate histopathology, immunohistochemistry, and rapidly expanding biomarker testing. More...

As patients live longer and undergo repeated analyses across institutions, these reports can become lengthy and difficult to synthesize under time pressure. Omitting molecular or genomic details can affect treatment selection and documentation quality. A new study shows that artificial intelligence can produce more complete summaries of these complex cancer reports.

Northwestern University Feinberg School of Medicine (Chicago, IL, USA) researchers evaluated open-source large language models (LLMs) for automatically summarizing cancer pathology reports. The approach centers on using LLMs to convert free‑text narratives into structured, clinician‑oriented summaries. The findings were published in JCO Clinical Cancer Informatics on April 8, 2026.

The technology tested included six downloadable, locally runnable LLMs: Meta’s Llama 3.0, 3.1, and 3.2 models; Google’s Gemma 9B; Mistral 7.2B; and DeepSeek‑R1. These systems parsed the text of de‑identified reports and generated summaries that captured key domains such as histopathological descriptions, immunohistochemical results, and molecular and genetic data relevant to treatment. The goal was to standardize extraction of clinically salient details that can otherwise be scattered across lengthy documents.

Investigators analyzed 94 de‑identified pathology reports from lung cancer patients and compared the AI‑generated summaries with clinical summaries previously written by physicians. A panel of oncologists assessed each summary for accuracy, completeness, conciseness, and potential clinical risk. Across models, AI‑generated summaries were consistently rated as more complete, with the most pronounced gains in inclusion of molecular and genomic findings; DeepSeek and Llama 3.1 performed best among the models evaluated.

The authors describe the innovation as a support layer to augment, not replace, clinical expertise by highlighting key findings, identifying missing information, and improving consistency in documentation. They note ongoing development of an application using Llama 3.1 to enable clinician review of AI‑generated summaries, with additional testing and validation planned prior to deployment.

“As cancer care becomes increasingly complex, the burden of synthesizing complex reports is growing rapidly. What we’re seeing is that AI can help ensure critical pathological and genomic details are consistently captured—not as a replacement for physicians, but as a tool to augment clinical decision-making,” said Mohamed Abazeed, chair and professor of radiation oncology at Northwestern University Feinberg School of Medicine.

“If AI can reliably synthesize these reports, clinicians can review key findings more efficiently, important genetic details are less likely to be overlooked and documentation becomes more standardized. This could help physicians focus more on patient care,” said Troy Teo, instructor of radiation oncology at Feinberg.

Related Links
Northwestern University Feinberg School of Medicine


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Gold Member
Quantitative lmmunoassay Test Menu
POC Immunoassay Analyzer
Procise DX
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Tracking blood test trends alongside unexplained weight loss may help identify patients at increased cancer risk and support earlier investigation (Image Credit: 123RF)

Blood Test Patterns Improve Cancer Risk Assessment in Primary Care

Unexplained weight loss is a common but nonspecific presentation in primary care that can precede several types of cancer, making referral decisions difficult. Routine blood tests may produce borderline... Read more

Molecular Diagnostics

view channel
Image: NTM are about 200 environmental bacteria found in soil and water that can cause chronic, tuberculosis-like lung infections but are distinct from the Mycobacterium tuberculosis complex (Image Credit: Adobe Stock)

Rapid CRISPR Test Identifies Nontuberculous Mycobacteria Species from Respiratory Samples

Chronic lung infections caused by nontuberculous mycobacteria (NTM) are increasingly recognized but frequently mistaken for tuberculosis, complicating diagnosis and care. These infections may affect as... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.